Hugel ve Medica, MENA'da Botulinum Toksin Satışlarını Artıracak

Hugel Inc., a leading firm in the global medical aesthetics sector, has announced the establishment of a strategic partnership with Medica Group, a Dubai-based aesthetic and medical distribution partner, to accelerate growth in the botulinum toxin market across the Middle East and North Africa (MENA) region.

The two companies recently concluded an agreement to strengthen the distribution of Hugel's Botulax toxin in key markets across the region. Hugel exports its toxin to 64 markets, including three of the world's largest toxin markets in the United States, Europe and China. The company had obtained sales approval for Botulax in the Middle East in the preceding year.

Medica Group is among the region's leading companies, with a strong distribution network through its headquarters in the United Arab Emirates (UAE) and branches in Saudi Arabia and Lebanon. The firm demonstrates solid expertise and strong operational capabilities in the field by distributing medical aesthetics products from approximately 30 global brands.

The MENA region stands out as one of the fastest-growing regions in medical aesthetics, driven by strong economic momentum, favorable demographic characteristics, increasing access to social media, and shifts in social and consumer trends.

Suk Cha, Chairman of the Executive Board of Hugel, made the following statement regarding the collaboration:
“We are pleased to sign this strategic collaboration with Medica Group. The Middle East represents an important market for Hugel, given the rapidly increasing demand for medical aesthetics treatments. We selected Medica Group as our distribution partner because they share our commitment to excellence and quality. Their deep understanding of the region, proven expertise and extensive reach network make them an ideal partner for bringing our Botulax product to this dynamic region. Botulax is recognized worldwide for its quality, and we believe that through this collaboration, it will become a preferred choice for medical professionals and patients in the Middle East and

Africa.”

Andre Daoud, CEO of Medica Group, emphasized the significance of this collaboration:
“Our partnership with Hugel represents an important turning point for us as we continue to expand our portfolio and lead the aesthetics market with global solutions. The introduction of Botulax to the Middle East and Africa offers healthcare professionals a world-standard botulinum toxin that is highly trusted for its quality, safety and performance. This strategic partnership aligns with our mission to deliver advanced, innovative products and services that meet the demands of the region's growing beauty and medical aesthetics market. The combination of Hugel's global expertise with our deep local knowledge and network will create tremendous value for our customers and patients.”